Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: A multicenter propensity score analysis

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Yoshimura, Jumpei ^a   Yamakawa, Kazuma ^a   Ogura, Hiroshi ^b   Umemura, Yutaka ^a   Takahashi, Hiroki ^b   Morikawa, Miki ^c   Inoue, Yoshiaki ^c   Fujimi, Satoshi ^a   Tanaka, Hiroshi ^c   Hamasaki, Toshimitsu ^d   Shimazu, Takeshi ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN; THROMBOMODULIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ADULT; AGED; APACHE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS INDUCED DISSEMINATED INTRAVASCULAR COAGULATION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TERTIARY CARE CENTER; CLINICAL TRIAL; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; HOSPITAL MORTALITY; INTENSIVE CARE UNIT; MIDDLE AGED; REGRESSION ANALYSIS; SEPSIS; TREATMENT OUTCOME;

AGED; APACHE; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROPENSITY SCORE; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEPSIS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84928226163     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0810-3     Document Type: Article

References (18)

1. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864-75.
2. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-30.
3. Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, et al. SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock. 2007;28:411-7.
4. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64.
5. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, López Rodriguez A, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47.
6. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.
7. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34:285-92.
8. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein CEPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol. 2004;24:1374-83.
9. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 2013;39:644-52.
10. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41:2069-79.
11. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-31.
12. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004;30:536-55.
13. D'Agostino Jr RB, D'Agostino Sr RB. Estimating treatment effects using observational data. JAMA. 2007;297:314-6.
14. Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36:1993-2003.
15. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003;29:894-903.
16. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
17. Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
18. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-41.